Transplant Connect, the world’s leading software provider for the donation and transplantation field, is pleased to announce an investment from InVita Healthcare Technologies. InVita provides leading chain of custody software for complex medical environments including blood, plasma, tissue, implant, and forensic DNA. This strategic investment will help accelerate the continued expansion of Transplant Connect’s iTransplant clinical information, communications, analytics and logistics platform and its many innovations, such as the company’s iReferral℠ automated donor referral technology.
“We welcome Transplant Connect and its world-class products to InVita’s robust portfolio serving complex medical environments,” said Todd Collins, President and CEO of InVita. “Software that manages mission-critical operations, such as for human organ, tissue, eye and birth tissue donation and transplant is a natural fit for InVita. This investment furthers our mission to deliver the most innovative and comprehensive solutions for managing complex medical workflows. We are proud to be working with the leader in this space.”
The iTransplant Platform supports nearly 75% of all deceased organ, tissue and eye donation in the United States and is used by more than 12,500 medical professionals across more than 100 organ, tissue, eye and birth tissue organizations around the world.
“We are truly excited by this investment from InVita,” said John Piano, Founder, Chairman and CEO, Transplant Connect. “Through this investment, we’ll be able to expand vital resources and capabilities and meaningfully grow our innovation – allowing us to further connect the donation and transplant ecosystem and help save and heal more lives in the U.S. and around the world. Our combined resources will allow us to build on Transplant Connect’s unparalleled 17+ years of success and take our offerings to the next level.”
Read More: Apteco & Syniverse Collaborate to Offer WhatsApp as a Channel for Marketing Automation